Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
Conclusion: Our findings, along with other reports, suggest that MKIs is an effective neoadjuvant therapy and should be considered as a therapeutic strategy for unresectable grossly locally invasive thyroid carcinomas.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Endocrinology | Esophagus Cancer | Iodine | Neoadjuvant Therapy | PET Scan | Study | Thyroid | Thyroid Cancer | Thyroidectomy | Tracheal Cancer